Q1 Earnings Forecast for NERV Issued By HC Wainwright

Minerva Neurosciences, Inc (NASDAQ:NERV) – Equities research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Minerva Neurosciences in a research report issued on Thursday, March 12th. HC Wainwright analyst D. Tsao anticipates that the biopharmaceutical company will post earnings of ($0.11) per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $7.00 price target on the stock. The consensus estimate for Minerva Neurosciences’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Minerva Neurosciences’ Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.12) EPS, Q4 2027 earnings at ($0.13) EPS, FY2029 earnings at $0.63 EPS and FY2030 earnings at $1.71 EPS.

Minerva Neurosciences (NASDAQ:NERV) last released its earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.75.

Several other equities research analysts have also recently weighed in on NERV. Wall Street Zen upgraded shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Minerva Neurosciences in a report on Monday, December 29th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $7.00.

Minerva Neurosciences Stock Performance

Shares of NASDAQ NERV opened at $7.83 on Friday. The company has a market capitalization of $338.80 million, a P/E ratio of -0.29 and a beta of -0.31. Minerva Neurosciences has a 52-week low of $1.15 and a 52-week high of $12.46. The company’s 50 day moving average price is $5.49 and its 200-day moving average price is $4.08.

Institutional Trading of Minerva Neurosciences

Large investors have recently modified their holdings of the stock. Apella Capital LLC increased its stake in shares of Minerva Neurosciences by 7.8% in the 4th quarter. Apella Capital LLC now owns 42,380 shares of the biopharmaceutical company’s stock valued at $170,000 after acquiring an additional 3,066 shares in the last quarter. State Street Corp boosted its stake in Minerva Neurosciences by 45.4% during the fourth quarter. State Street Corp now owns 24,019 shares of the biopharmaceutical company’s stock worth $97,000 after acquiring an additional 7,500 shares in the last quarter. Janus Henderson Group PLC bought a new position in Minerva Neurosciences during the fourth quarter worth $36,000. Renaissance Technologies LLC grew its holdings in Minerva Neurosciences by 28.1% in the fourth quarter. Renaissance Technologies LLC now owns 149,200 shares of the biopharmaceutical company’s stock worth $600,000 after purchasing an additional 32,700 shares during the period. Finally, Millennium Management LLC acquired a new stake in Minerva Neurosciences in the fourth quarter worth $554,000. Institutional investors and hedge funds own 34.56% of the company’s stock.

Key Minerva Neurosciences News

Here are the key news stories impacting Minerva Neurosciences this week:

• Positive Sentiment: HC Wainwright raised several multi-year forecasts (FY2027, FY2028, FY2029, FY2030), signaling a more constructive long-term earnings trajectory that could support upside if clinical or commercialization catalysts materialize. (Analyst: D. Tsao)
• Positive Sentiment: The firm slightly improved its Q1 2026 EPS estimate (from ($0.14) to ($0.13)), which is a small near-term beat in the model and may be read as incremental progress on the company’s path to profitability.
• Neutral Sentiment: HC Wainwright maintained a Neutral rating and a $7.00 price target, leaving the official analyst view and price objective unchanged — this limits the forcefulness of the report’s impact on the stock.
• Negative Sentiment: Near-term guidance was downgraded: Q2, Q3 and Q4 2026 and full-year FY2026 EPS estimates were lowered (FY2026 now forecast at ($0.60) vs prior ($0.54)), reflecting a weaker 2026 profitability outlook that could pressure sentiment if investors focus on short-term cash burn and milestones.
• Negative Sentiment: Several quarterly 2026 estimates were trimmed (Q2 to ($0.18) from ($0.15); Q3 to ($0.18) from ($0.16); Q4 to ($0.11) from ($0.09)), indicating the analyst sees a bump in near-term losses before the later-year improvements.

About Minerva Neurosciences

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.